Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course

  • Gil Varea, Elia|||0000-0001-5144-4144
  • Urcelay, Elena|||0000-0001-8470-8396
  • Vilariño-Güell, Carles|||0000-0002-5612-5940
  • Costa, Carme|||0000-0001-9577-3839
  • Midaglia, Luciana|||0000-0001-7981-2228
  • Matesanz, Fuencisla|||0000-0002-9429-1819
  • Rodríguez Antigüedad, Alfredo|||0000-0001-5975-725X
  • Oksenberg, Jorge
  • Espino-Paisan, Laura
  • Dessa Sadovnick, A.
  • Saiz, Albert|||0000-0002-5793-8791
  • Villar, Luisa M.|||0000-0002-9067-3668
  • García Merino, Juan Antonio
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Triviño, Juan Carlos
  • Quintana, Ester|||0000-0001-8885-1931
  • Robles, René
  • Sánchez López, Antonio José|||0000-0001-7168-6175
  • Arroyo, Rafael
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Malhotra, Sunny|||0000-0003-1112-7739
  • Fissolo, Nicolás|||0000-0002-7701-9346
  • Montalban, Xavier|||0000-0002-0098-9918
  • Comabella López, Manuel|||0000-0002-2373-6657
It remains unclear whether disease course in multiple sclerosis (MS) is influenced by genetic polymorphisms. Here, we aimed to identify genetic variants associated with benign and aggressive disease courses in MS patients. MS patients were classified into benign and aggressive phenotypes according to clinical criteria. We performed exome sequencing in a discovery cohort, which included 20 MS patients, 10 with benign and 10 with aggressive disease course, and genotyping in 2 independent validation cohorts. The first validation cohort encompassed 194 MS patients, 107 with benign and 87 with aggressive phenotypes. The second validation cohort comprised 257 patients, of whom 224 patients had benign phenotypes and 33 aggressive disease courses. Brain immunohistochemistries were performed using disease course associated genes antibodies. By means of single-nucleotide polymorphism (SNP) detection and comparison of allele frequencies between patients with benign and aggressive phenotypes, a total of 16 SNPs were selected for validation from the exome sequencing data in the discovery cohort. Meta-analysis of genotyping results in two validation cohorts revealed two polymorphisms, rs28469012 and rs10894768, significantly associated with disease course. SNP rs28469012 is located in CPXM2 (carboxypeptidase X, M14 family, member 2) and was associated with aggressive disease course (uncorrected p value < 0.05). SNP rs10894768, which is positioned in IGSF9B (immunoglobulin superfamily member 9B) was associated with benign phenotype (uncorrected p value < 0.05). In addition, a trend for association with benign phenotype was observed for a third SNP, rs10423927, in NLRP9 (NLR family pyrin domain containing 9). Brain immunohistochemistries in chronic active lesions from MS patients revealed expression of IGSF9B in astrocytes and macrophages/microglial cells, and expression of CPXM2 and NLRP9 restricted to brain macrophages/microglia. Genetic variants located in CPXM2, IGSF9B, and NLRP9 have the potential to modulate disease course in MS patients and may be used as disease activity biomarkers to identify patients with divergent disease courses. Altogether, the reported results from this study support the influence of genetic factors in MS disease course and may help to better understand the complex molecular mechanisms underlying disease pathogenesis. The online version of this article (10.1186/s12974-018-1307-1) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab

  • Toboso, Inmaculada
  • Tejeda-Velarde, Amalia
  • Alvarez-Lafuente, Roberto|||0000-0002-3132-1486
  • Arroyo, Rafael
  • Hegen, Harald
  • Deisenhammer, Florian|||0000-0003-4541-8841
  • Sainz De La Maza, Susana
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Izquierdo, Guillermo|||0000-0002-6340-5609
  • Paramo, Dolores
  • Oliva, Pedro
  • Casanova, Bonaventura|||0000-0003-3806-925X
  • Agüera-Morales, Eduardo|||0000-0002-8604-2054
  • Franciotta, Diego
  • Gastaldi, Matteo
  • Fernández Fernández, Óscar|||0000-0003-3696-789X
  • Urbaneja, Patricia
  • García Domínguez, José Manuel
  • Romero, Fernando
  • Laroni, Alicia
  • Uccelli, Antonio
  • Perez-Sempere, Angel|||0000-0002-0195-2834
  • Saiz, Albert|||0000-0002-5793-8791
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Galimberti, Daniela|||0000-0002-9284-5953
  • Scarpini, Elio|||0000-0002-6395-2119
  • Espejo, Carmen|||0000-0001-9949-5901
  • Montalban, Xavier|||0000-0002-0098-9918
  • Rasche, Ludwig
  • Paul, Friedemann|||0000-0002-6378-0070
  • González, Inés
  • Álvarez, Elena
  • Ramo-Tello, Cristina|||0000-0001-8643-5053
  • Caminero, Ana B.
  • Aladro, Yolanda|||0000-0001-9459-5452
  • Calles, Carmen
  • Eguía, Pablo
  • Belenguer Benavides, Antonio|||0000-0003-2763-8218
  • Ramió-Torrentà, Lluís|||0000-0002-6999-1004
  • Quintana, Ester|||0000-0001-8885-1931
  • Martínez-Rodríguez, José E.
  • Oterino, Agustín|||0000-0002-7457-9129
  • López de Silanes, Carlos
  • Casanova, Luis I.
  • Landete Pascual, Lamberto
  • Frederiksen, Jette
  • Bsteh, Gabriel
  • Mulero, Patricia|||0000-0001-8716-8997
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Hernández, Miguel A.
  • Espiño, Mercedes
  • Prieto, José M.
  • Pérez, Domingo
  • Otano-Martínez, María A.
  • Padilla, Francisco
  • García Merino, Juan Antonio
  • Navarro Canto, Laura
  • Muriel, Alfonso|||0000-0002-4805-4011
  • Frossard, Lucienne Costa
  • Villar, Luisa M.|||0000-0002-9067-3668
Overview: We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple sclerosis patients treated with natalizumab in 36 University Hospitals in Europe. We performed the study in 1,307 multiple sclerosis patients (70.8% anti-John Cunninghan virus positive antibodies) treated with natalizumab for a median time of 3.28 years. Epidemiological, clinical, and laboratory variables were collected. Lipid-specific IgM oligoclonal band status was available in 277 patients. Factors associated with progressive multifocal leucoencephalopathy onset were explored by uni- and multivariate logistic regression. Results: Thirty-five patients developed progressive multifocal leucoencephalopathy. The multivariate analysis identified anti-John Cunninghan virus antibody indices and relapse rate as the best predictors for the onset of this serious opportunistic infection in the whole cohort. They allowed to stratify progressive multifocal leucoencephalopathy risk before natalizumab initiation in individual patients [area under the curve (AUC) = 0.85]. The risk ranged from <1/3,300 in patients with anti-John Cunninghan virus antibody indices <0.9 and relapse rate.